Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court

The Roche Biocon Perjeta lawsuit has become the latest flashpoint in the escalating global fight over biosimilar competition to one of oncology’s best-selling antibody drugs. Genentech Inc. and its parent Hoffmann-La Roche filed a new patent infringement complaint against Indian biopharmaceutical company Biocon in the U.S. District Court for the District of New Jersey, according to Reuters, accusing Biocon’s proposed biosimilar of copying the science behind Perjeta, Roche’s blockbuster HER2-positive breast-cancer treatment.

The filing marks the second major U.S. legal action Genentech has brought against Biocon over the same pertuzumab biosimilar candidate in under six months, following a separate complaint at the International Trade Commission earlier in 2026. Genentech is asking the New Jersey court to block Biocon from manufacturing or commercially launching the copycat product until the underlying patents run their course.

For a company that built its reputation on Herceptin and Avastin, Perjeta has become one of Roche’s most closely guarded franchises, and the Roche Biocon Perjeta lawsuit signals that the Swiss drugmaker intends to defend that turf in every available forum, from federal district court to the trade commission, as biosimilar rivals close in on a drug still generating billions in annual sales.

According to the complaint reported by Reuters, Genentech and Roche allege that Biocon’s pertuzumab biosimilar candidate, would infringe multiple patents covering Perjeta’s antibody composition and manufacturing process. The lawsuit is structured as a patent-infringement action under the framework used for biologic drugs, giving the branded manufacturer a legal pathway to challenge a biosimilar applicant before the copy reaches pharmacy shelves.

Learn More

FDA Accepts Priority Review for Roche Giredestrant in Early-Stage Breast Cancer

This new district court filing follows a narrower complaint Genentech lodged with the U.S. International Trade Commission in February 2026, which focused on Biocon’s alleged importation of commercial-scale quantities of the same biosimilar candidate from India before it had secured FDA approval. That ITC case cited a shipment of more than 17,800 units recorded in FDA import data and argued the volume amounted to stockpiling rather than activity protected under patent law’s regulatory safe harbor.

Biocon has not publicly detailed its response to the newest filing. The Roche Biocon Perjeta lawsuit now proceeds on two fronts simultaneously: a district court case seeking an injunction and damages, and an ITC proceeding seeking to block the product’s importation into the United States entirely.

Perjeta’s Multibillion-Franc Franchise Faces Biosimilar Pressure

Perjeta remains one of Roche’s most valuable oncology assets. The drug, used alongside Herceptin and chemotherapy to treat HER2-positive breast cancer, generated global sales of close to 3 billion Swiss francs in 2025, though industry analysts have tracked a gradual decline from the drug’s 2021 peak as biosimilar competition began to take shape. That erosion is precisely what has pushed Roche and Genentech into an increasingly aggressive litigation posture wherever a rival biosimilar surfaces, and the Roche Biocon Perjeta lawsuit is the clearest recent example of that posture in practice.

The pressure intensified in November 2025, when the FDA approved the first interchangeable biosimilar referencing Perjeta, developed by Shanghai Henlius Biotech in partnership with Organon. That approval came after Genentech and Roche had already sued the pair in August 2025 in the same New Jersey federal court, asserting infringement of two dozen patents. The parties reached a settlement in January 2026, clearing the way for the Henlius-Organon product’s commercial launch.

Biocon’s proposed biosimilar is now positioned to become a second entrant into the same market, and the timing of the Roche Biocon Perjeta lawsuit suggests Genentech wants to replicate the same legal strategy: assert the full patent estate early, use the litigation to establish a negotiating position, and either force a delayed launch date or a licensing settlement before Biocon’s product reaches U.S. patients.

Learn More

Roche’s Gazyva Meets Primary Endpoint in Phase III ALLEGORY Study, Showing Significant Disease Control in Lupus

Biocon Biologics, the biosimilars arm of Bengaluru-based Biocon, has been party to a string of similar U.S. patent disputes in the past year, underscoring how central biosimilar litigation has become to its growth strategy. The company settled a denosumab biosimilar case with Amgen in the District of New Jersey in September 2025 and reached a global settlement with Regeneron over an aflibercept biosimilar in December 2025, resolving multi-district litigation that had been consolidated in West Virginia federal court.

Those earlier settlements allowed Biocon’s biosimilar versions of Amgen’s and Regeneron’s originator drugs to move toward the U.S. market on negotiated timelines, a pattern common across the biosimilar industry, where originator companies use patent litigation less to win outright and more to control the pace of competitive entry. The Roche Biocon Perjeta lawsuit fits that same template, though Roche’s parallel use of the International Trade Commission signals a somewhat harder line than the settlements Biocon secured with Amgen and Regeneron.

Legal trackers covering the biosimilar sector have noted that pertuzumab litigation is still relatively new territory compared with longer-running disputes over trastuzumab, adalimumab, and etanercept biosimilars, meaning courts have limited precedent specific to Perjeta patent challenges. That gives both sides an incentive to settle rather than risk an unpredictable ruling, though Roche’s decision to pursue Biocon in two forums at once suggests it is not yet ready to negotiate.

Roche shares traded modestly higher following the news, changing hands around 358 Swiss francs on the SIX exchange, suggesting investors do not view the litigation as a near-term threat to Perjeta revenue. Biocon has not issued a public statement responding to the New Jersey filing as of this writing.

The case will now move through standard BPCIA litigation procedure, discovery, claim construction, and potentially trial — unless the parties reach a settlement similar to the Henlius-Organon resolution. Given that Biocon’s pertuzumab biosimilar has not yet received FDA approval, any court-ordered delay could push a commercial U.S. launch well past the point the ITC case alone would have achieved, giving Genentech leverage on two separate timelines.

For patients and health systems watching biosimilar pricing, the outcome carries real stakes. Each new interchangeable pertuzumab biosimilar that reaches the market has historically driven meaningful discounts off the branded price, and a prolonged Roche Biocon Perjeta lawsuit could delay that pricing relief for HER2-positive breast-cancer patients relying on Perjeta-based regimens. Coverage of the case will be updated as the New Jersey court docket develops and as Biocon responds to the complaint.

Litigation Timeline